Register for our free email digests:
University of South Florida Research Foundation
Division of University of South Florida
Latest From Ewopharma AG
Analyst speculates that Gilead could move to acquire Spring Bank if combo trial yields promising data for functional cure of hepatitis B. Eisai in-licenses PARP inhibitor with potential in breast cancer from Oncology Venture, while Sunovion out-licenses three corticosteroid products to Covis.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.